How much pemetinib should be used in patients with cholangiocarcinoma?

Pemetinib (Pemetinib), trade name Dabotan, is a small molecule inhibitor targeting fibroblast growth factor receptor (FGFR). It is mainly used to treat patients with cholangiocarcinoma carrying FGFR2 gene fusion or rearrangement. It blocks the FGFR signaling pathway and inhibits the growth and spread of tumor cells, providing a new treatment option for cholangiocarcinoma patients. The launch of pemetinib marks a major advancement in the treatment of cholangiocarcinoma and brings new hope to patients who have poor response to traditional treatments.

For patients with cholangiocarcinoma, the recommended dosage and use of pemetinib must strictly follow the doctor's guidance. Usually, the recommended dose of pemetinib is 13.5 mg taken orally once daily for 14 days, followed by 7 days of discontinuation, forming a complete 21-day treatment cycle. This delivery method is designed to balance efficacy and safety to ensure that patients can maintain a good quality of life during treatment.

However, it is important to note that the actual dosage of pemetinib may be adjusted based on the patient's specific circumstances. For example, for patients with severely impaired liver and kidney function, doctors may recommend lowering the dose to 9 mg per day to avoid adverse reactions caused by excessive accumulation of the drug in the body. In addition, if a patient experiences unacceptable toxicity or disease progression during treatment, doctors may also consider adjusting the dose or interrupting treatment.

Therefore, patients with cholangiocarcinoma must strictly abide by the doctor's instructions when using pemetinib and are not allowed to change the dose or stop the drug on their own. At the same time, patients should also pay close attention to changes in physical conditions and report any discomfort or abnormal reactions to their doctors in a timely manner. Through rational use of medication and close monitoring, patients can better control their condition and improve their quality of life.

In short, the dosage of pemetinib for patients with cholangiocarcinoma needs to be adjusted individually according to the guidance of the doctor. Patients should maintain close communication with their doctors during use to ensure the safety and effectiveness of the treatment plan.